Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • bhatig
    Junior Member
    • Jun 2009
    • 2

    #1

    need help

    I was reading this patent which contained a training of a neural network the training set consisted of a set of genes and a set of non genes could you give me some information about non genes that is
    1.what are non genes?
    2. how can i get their sequences ?
    3. what kind of organisms have high number of non genes?
    4.are pseudo genes same as non genes?


    Patent and Paragraph details
    publication number :US 2005 /0136480 A1
    publication date 23rd june 2005
    paragraph no [0081]

    paragraph text
    "The training set' consists of 1610 E coli .K-12
    NCBI listed protein coding genes and 3000 F. E coli .K-12
    ORFS (a stretch of sequence of length more than 20 amino
    acids and having start codon, stop codon in the same frame)
    which have not been reported as genes (non-genes).
    The
    validation set has 1000 known genes and 1000 non-genes
    from E coli .K-12 distinct from those used in the training set.
    The test set contains another 1000 genes and 1000 nongenes
    from the same organism. For training of the ANN,
    genes and the non-genes are assigned a probability value of
    1 and 0 respectively."

    Can anybody explain me
    what this paragraph means i.e., from where I get these 3000 non-genes
  • lry198010
    Member
    • Aug 2008
    • 13

    #2
    I think the paragraph means that: the listed protein coding genes are consider as genes and the ones listed as ORFS are consider as non-genes in the training and testing. The genes and non-genes are come from NCBI GENBANK, the method to determine gene and non-gene are based the Genome annotation. But my question it's that: there are total 1610 genes in the analysis and the first 1000 genes was used as training set, so the number of the remain genes is 1610-1000=610, and how do the authors to get another 390 genes in the testing.

    Comment

    • bhatig
      Junior Member
      • Jun 2009
      • 2

      #3
      thanx for reply...i don't know answer of your question but will give as soon as i get...as we are trying to contact the authors of the patent..plz do reply if you get something else..
      thanx

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
        by SEQadmin2



        CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

        Despite this, “CRISPR helped turn genome editing from a specialized technique into
        ...
        Today, 11:01 AM
      • SEQadmin2
        Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
        by SEQadmin2


        Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

        The systematic characterization of the human proteome has
        ...
        07-20-2026, 11:48 AM
      • SEQadmin2
        Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
        by SEQadmin2



        Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
        ...
        07-09-2026, 11:10 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, Today, 02:55 AM
      0 responses
      8 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-24-2026, 12:17 PM
      0 responses
      12 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-23-2026, 11:41 AM
      0 responses
      12 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-20-2026, 11:10 AM
      0 responses
      24 views
      0 reactions
      Last Post SEQadmin2  
      Working...